Table 4

Arz and LG268 synergize in treatment of advanced invasive breast cancer in rats

TreatmentaNo. of tumor-free rats/total no. of rats (P1; P2)bAverage no. of tumors (P1; P2)ATBc (P1; P2)Rats with 3 or more tumors (P1; P2)Rats with tumor burden > 5 g (P1; P2)
Control (vehicle)0/385.522.737/3836/38
Arz (60)d0/313.7 (<0.0001)10.2 (0.0001)23/31 (0.009)22/31 (0.009)
LG268 (200)2/312.8 (<0.0001)6.1 (<0.0001)17/31 (<0.0001)12/31 (<0.0001)
Arz (60) + LG268 (200)1/31 (0.5; 1.0)2.2 (<0.0001; 0.0005)1.5 (<0.0001; <0.0001)9/31 (<0.0001; 0.0008)2/31 (<0.0001; <0.0001)
  • a All rats received NMU (50 mg/kg, i.p.) when they were 21 days old. All tumors were measured weekly by calipers. When tumors were > 20 × 20 mm, rats were randomly assigned to treatment groups and fed chemopreventive agents for 5 weeks before autopsy.

  • b P1 is the value for the comparison of rats treated with chemopreventive agents with control rats treated with vehicle alone; P2 is the value for the comparison of rats treated with Arz + LG268 with rats treated with Arz alone.

  • c ATB, average tumor burden (average weight in grams of a rat’s tumor at autopsy).

  • d All doses are shown as mg/kg diet.